FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2979287557> ?p ?o ?g. }

• W2979287557 endingPage "v864" @default.
• W2979287557 startingPage "v864" @default.
• W2979287557 abstract "Abstract Background Metastatic cancer is one of the major causes of death and is associated with poor treatment efficiency. A better understanding of the characteristics of late stage cancer is required to help tailor personalised treatment, reduce overtreatment and improve outcomes. Methods Here we describe the largest pan-cancer study of metastatic solid tumor genomes, including 2,520 whole genome-sequenced tumor-normal pairs, analyzed at a median depth of 106x and 38x respectively, and surveying over 70 million somatic variants. Results Metastatic lesions were found to be very diverse, with mutation characteristics reflecting those of the primary tumor types, although with high rates of whole genome duplication events (56%). Metastatic lesions are relatively homogeneous with the vast majority (96%) of driver mutations being clonal and up to 80% of tumor suppressor genes bi-allelically inactivated through different mutational mechanisms. For 62% of all patients, genetic variants that may be associated with outcome of approved or experimental therapies were detected. These actionable events were distributed over the various mutation types (single and multiple nucleotide variants, insertions and deletions, copy number alterations and structural variants) underlining the importance of comprehensive genomic tumor profiling for cancer precision medicine for advanced cancer treatment. Conclusions Whole genome sequencing on fresh biopsies of metastatic cancer is feasible and identifies not only new insights in genome biology but also new opportunities for patients with both approved and experimental agents. We have created the largest data base of whole genome sequenced metastatic cancer patients which continues to facilitate new precision medicine studies. Legal entity responsible for the study The authors. Funding Hartwig Medical Foundation, Barcode for Life, Dutch Cancer Society. Disclosure E. Cuppen: Honoraria (self), Advisory / Consultancy: InteRNA technologies BV; Honoraria (institution), Advisory / Consultancy: Illumina; Full / Part-time employment, Officer / Board of Directors: Hartwig Medical Foundation. M.P. Lolkema: Advisory / Consultancy: Incyte; Advisory / Consultancy: Amgen; Advisory / Consultancy: Janssen Cilag BV; Advisory / Consultancy: Bayer; Advisory / Consultancy: Pfizer; Advisory / Consultancy: Sanofi Aventis Netherlands BV. P. Roepman: Honoraria (institution), Advisory / Consultancy: Illumina. V.C.G. Tjan-Heijnen: Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: E. Lilly; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Roche; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Novartis; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Pfizer; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: AstraZeneca. C. van Herpen: Advisory / Consultancy: Bayer; Advisory / Consultancy: BMS; Advisory / Consultancy: Ipsen ; Advisory / Consultancy: MSD; Advisory / Consultancy: Regeneron; Research grant / Funding (self): AstraZeneca; Research grant / Funding (self): BMS ; Research grant / Funding (self): MSD; Research grant / Funding (self): Merck; Research grant / Funding (self): Ipen; Research grant / Funding (self): Novartis ; Research grant / Funding (self): Sanofi . E.F. Smit: Honoraria (institution): AstraZeneca ; Honoraria (institution): BMC; Honoraria (institution): Bayer; Honoraria (institution): Eli Lilly ; Honoraria (institution): MSD; Honoraria (institution): Merck ; Honoraria (institution): Novartis; Honoraria (institution): Pfizer; Honoraria (institution): Takeda; Honoraria (institution): Regeneron; Honoraria (institution): Roche ; Honoraria (institution): Seattle Genetrics; Advisory / Consultancy: Eli Lilly ; Research grant / Funding (institution): AstraZeneca; Research grant / Funding (institution): BMS; Research grant / Funding (institution): Merck; Research grant / Funding (institution): MSD; Research grant / Funding (institution): Roche. All other authors have declared no conflicts of interest." @default.
• W2979287557 created "2019-10-10" @default.
• W2979287557 creator A5000355154 @default.
• W2979287557 creator A5019928738 @default.
• W2979287557 creator A5022815480 @default.
• W2979287557 creator A5026275940 @default.
• W2979287557 creator A5032131062 @default.
• W2979287557 creator A5043481012 @default.
• W2979287557 creator A5045932834 @default.
• W2979287557 creator A5047837719 @default.
• W2979287557 creator A5051744290 @default.
• W2979287557 creator A5054754505 @default.
• W2979287557 creator A5056760175 @default.
• W2979287557 creator A5058463503 @default.
• W2979287557 creator A5060207753 @default.
• W2979287557 creator A5072084304 @default.
• W2979287557 creator A5074521068 @default.
• W2979287557 creator A5078332643 @default.
• W2979287557 creator A5084198778 @default.
• W2979287557 creator A5084480894 @default.
• W2979287557 creator A5087288564 @default.
• W2979287557 creator A5089042997 @default.
• W2979287557 date "2019-10-01" @default.
• W2979287557 modified "2023-10-01" @default.
• W2979287557 title "Pan-cancer whole genome analyses of metastatic solid tumors" @default.
• W2979287557 doi "https://doi.org/10.1093/annonc/mdz394.015" @default.
• W2979287557 hasPublicationYear "2019" @default.
• W2979287557 type Work @default.
• W2979287557 sameAs 2979287557 @default.
• W2979287557 citedByCount "0" @default.
• W2979287557 crossrefType "journal-article" @default.
• W2979287557 hasAuthorship W2979287557A5000355154 @default.
• W2979287557 hasAuthorship W2979287557A5019928738 @default.
• W2979287557 hasAuthorship W2979287557A5022815480 @default.
• W2979287557 hasAuthorship W2979287557A5026275940 @default.
• W2979287557 hasAuthorship W2979287557A5032131062 @default.
• W2979287557 hasAuthorship W2979287557A5043481012 @default.
• W2979287557 hasAuthorship W2979287557A5045932834 @default.
• W2979287557 hasAuthorship W2979287557A5047837719 @default.
• W2979287557 hasAuthorship W2979287557A5051744290 @default.
• W2979287557 hasAuthorship W2979287557A5054754505 @default.
• W2979287557 hasAuthorship W2979287557A5056760175 @default.
• W2979287557 hasAuthorship W2979287557A5058463503 @default.
• W2979287557 hasAuthorship W2979287557A5060207753 @default.
• W2979287557 hasAuthorship W2979287557A5072084304 @default.
• W2979287557 hasAuthorship W2979287557A5074521068 @default.
• W2979287557 hasAuthorship W2979287557A5078332643 @default.
• W2979287557 hasAuthorship W2979287557A5084198778 @default.
• W2979287557 hasAuthorship W2979287557A5084480894 @default.
• W2979287557 hasAuthorship W2979287557A5087288564 @default.
• W2979287557 hasAuthorship W2979287557A5089042997 @default.
• W2979287557 hasBestOaLocation W29792875571 @default.
• W2979287557 hasConcept C104317684 @default.
• W2979287557 hasConcept C121608353 @default.
• W2979287557 hasConcept C126322002 @default.
• W2979287557 hasConcept C141231307 @default.
• W2979287557 hasConcept C143998085 @default.
• W2979287557 hasConcept C2993640289 @default.
• W2979287557 hasConcept C54355233 @default.
• W2979287557 hasConcept C70721500 @default.
• W2979287557 hasConcept C71924100 @default.
• W2979287557 hasConcept C86803240 @default.
• W2979287557 hasConceptScore W2979287557C104317684 @default.
• W2979287557 hasConceptScore W2979287557C121608353 @default.
• W2979287557 hasConceptScore W2979287557C126322002 @default.
• W2979287557 hasConceptScore W2979287557C141231307 @default.
• W2979287557 hasConceptScore W2979287557C143998085 @default.
• W2979287557 hasConceptScore W2979287557C2993640289 @default.
• W2979287557 hasConceptScore W2979287557C54355233 @default.
• W2979287557 hasConceptScore W2979287557C70721500 @default.
• W2979287557 hasConceptScore W2979287557C71924100 @default.
• W2979287557 hasConceptScore W2979287557C86803240 @default.
• W2979287557 hasLocation W29792875571 @default.
• W2979287557 hasLocation W29792875572 @default.
• W2979287557 hasOpenAccess W2979287557 @default.
• W2979287557 hasPrimaryLocation W29792875571 @default.
• W2979287557 hasRelatedWork W1980578041 @default.
• W2979287557 hasRelatedWork W2200318732 @default.
• W2979287557 hasRelatedWork W2238553258 @default.
• W2979287557 hasRelatedWork W2340204314 @default.
• W2979287557 hasRelatedWork W2582968398 @default.
• W2979287557 hasRelatedWork W2884856132 @default.
• W2979287557 hasRelatedWork W3016712940 @default.
• W2979287557 hasRelatedWork W4211093350 @default.
• W2979287557 hasRelatedWork W4313598112 @default.
• W2979287557 hasRelatedWork W4377098514 @default.
• W2979287557 hasVolume "30" @default.
• W2979287557 isParatext "false" @default.
• W2979287557 isRetracted "false" @default.
• W2979287557 magId "2979287557" @default.
• W2979287557 workType "article" @default.